Literature DB >> 10441395

Oxidation of clozapine and ascorbate by myeloperoxidase.

Y Hsuanyu1, H B Dunford.   

Abstract

The kinetics and spectra of the reactions of clozapine with compounds I and II of myeloperoxidase were investigated using both single- and sequential-mixing stopped-flow techniques, steady-state kinetics, and spectrophotometric measurements. The results show conclusively that both compounds I and II are reduced in one-electron reactions with clozapine. At pH 7.0 the rate constant for compound I reacting with clozapine is (1.5 +/- 0.1) x 10(6) M(-1) s(-1) and for compound II (4.8 +/- 0.1) x 10(4) M(-1) s(-1). The physiological pH of 7.4 was found to be optimal for the oxidation of clozapine by compound I. The rate constant for compound I reacting with ascorbate is (1.1 +/- 0.1) x 10(6) M(-1) s(-1) and for compound II (1.1 +/- 0.2) x 10(4) M(-1) s(-1), both obtained at pH 7.0. Experiments with both clozapine and ascorbate present showed that ascorbate acts both as a competitive inhibitor and free radical scavenger. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10441395     DOI: 10.1006/abbi.1999.1328

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  12 in total

Review 1.  Oxidases and oxygenases in regulation of vascular nitric oxide signaling and inflammatory responses.

Authors:  Mutay Aslan; Bruce A Freeman
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Urate as a physiological substrate for myeloperoxidase: implications for hyperuricemia and inflammation.

Authors:  Flavia C Meotti; Guy N L Jameson; Rufus Turner; D Tim Harwood; Samantha Stockwell; Martin D Rees; Shane R Thomas; Anthony J Kettle
Journal:  J Biol Chem       Date:  2011-01-25       Impact factor: 5.157

3.  Vitamin C protects against and reverses specific hypochlorous acid- and chloramine-dependent modifications of low-density lipoprotein.

Authors:  A C Carr; T Tijerina; B Frei
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

4.  Investigating the mechanisms of aromatic amine-induced protein free radical formation by quantitative structure-activity relationships: implications for drug-induced agranulocytosis.

Authors:  Arno G Siraki; Jinjie Jiang; Ronald P Mason
Journal:  Chem Res Toxicol       Date:  2010-05-17       Impact factor: 3.739

Review 5.  Genetics of antipsychotic-induced side effects and agranulocytosis.

Authors:  Nabilah I Chowdhury; Gary Remington; James L Kennedy
Journal:  Curr Psychiatry Rep       Date:  2011-04       Impact factor: 5.285

6.  Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates.

Authors:  Louisa V Forbes; Tove Sjögren; Françoise Auchère; David W Jenkins; Bob Thong; David Laughton; Paul Hemsley; Garry Pairaudeau; Rufus Turner; Håkan Eriksson; John F Unitt; Anthony J Kettle
Journal:  J Biol Chem       Date:  2013-11-05       Impact factor: 5.157

7.  Human indoleamine 2,3-dioxygenase is a catalyst of physiological heme peroxidase reactions: implications for the inhibition of dioxygenase activity by hydrogen peroxide.

Authors:  Mohammed Freewan; Martin D Rees; Tito S Sempértegui Plaza; Elias Glaros; Yean J Lim; Xiao Suo Wang; Amanda W S Yeung; Paul K Witting; Andrew C Terentis; Shane R Thomas
Journal:  J Biol Chem       Date:  2012-12-03       Impact factor: 5.157

Review 8.  Myeloperoxidase: a target for new drug development?

Authors:  E Malle; P G Furtmüller; W Sattler; C Obinger
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

9.  Procainamide, but not N-acetylprocainamide, induces protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis.

Authors:  Arno G Siraki; Leesa J Deterding; Marcelo G Bonini; Jinjie Jiang; Marilyn Ehrenshaft; Kenneth B Tomer; Ronald P Mason
Journal:  Chem Res Toxicol       Date:  2008-05-19       Impact factor: 3.739

10.  Fucoxanthin in association with vitamin C acts as modulators of human neutrophil function.

Authors:  A C Morandi; N Molina; B A Guerra; A P Bolin; R Otton
Journal:  Eur J Nutr       Date:  2013-09-06       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.